PIPC submitted a letter to the Oregon Prescription Drug Affordability Board (PDAB) on the Board's ongoing affordability review activities.
On May 13, PIPC submitted a comment letter to the Maryland Prescription Drug Affordability Board (PDAB) on the Board's ongoing Cost Review Study process.
On May 7, PIPC submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of chronic obstructive pulmonary disease (COPD).
On February 6, 2024, PIPC submitted comments to the committees of jurisdiction in the Maryland House of Delegates and State Senate opposing legislation expanding the authority of the State Prescription Drug Affordability Board, and urging policymakers ban QALYs and similar measures.
|
Topics
All
Archives
May 2024
|